Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Clinical trial NCT03229200 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03229200
Sponsor: Pharmacyclics Switzerland GmbH
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 4
Study type: INTERVENTIONAL

Lymphoma, B-Cell Lymphoma, Non-Hodgkin Leukemia, B-cell Graft Vs Host Disease Solid Tumor

Start date: 2017-05-22
Primary completion: 2027-05-10
Enrollment: 297

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.